SAB Bio
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Florida, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
777 W 41st St Ste 401, Miami Beach, Flor...Phone Number
(605) 679-6980Website
sab.bioRevenue
-Stock Symbol
SABSIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
3
1
1
1
1
About SAB Bio
SAB Biotherapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing human polyclonal antibody therapeutics to treat and prevent infectious diseases and immune and autoimmune disorders. Headquartered in Sioux Falls, South Dakota, SAB Biotherapeutics has pioneered a proprietary platform technology called DiversitAb, which utilizes genetically engineered cattle to produce fully human polyclonal antibodies without using human donors. The company's innovative approach involves modifying cattle to produce large quantities of targeted human antibodies in response to specific antigens, creating a scalable and rapid response capability for emerging infectious diseases and other therapeutic applications. SAB Biotherapeutics has developed therapeutic candidates targeting various conditions including , influenza, and other viral infections, as well as exploring applications in autoimmune diseases and cancer. The company's platform offers advantages in speed of development,Read more
SAB Bio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is SAB Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at SAB Bio
Check out if SAB Bio is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if SAB Bio has recently received funding, and reach out quickly before it becomes old news!
Click to see if SAB Bio had a recent Job posting/layoffs
Product Launch: Get notified when SAB Bio launches new products
Funding: Get notified immidiatlly once SAB Bio has new funding data
SAB Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on SAB Bio recently announced quarterly report
Recommended Actions
Find VP level buyers at SAB Bio
Find 2 more new buyers
Compare Similar Companies to SAB Bio
Compare insights from companies similar to SAB Bio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
SAB Bio is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
SAB Bio is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about SAB Bio.
SAB Bio financials insights
Gather financial insights about SAB Bio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Other Financing Round
$3M
2016
Grant
$1.4M
2018
Series A
$22M
2020
Debt
$350K
Series B
$36.4M
2025
Private Equity
$175M
SAB Bio Tech Stack
A closer look at the technologies used by SAB Bio
Most Recent Scoops
Open Position
Open Position
Earnings
Earnings, Finance
Project
Laboratory Operations, Medical Research, Clinical Operations
Earnings
Earnings, Finance
SAB Bio News & Media
SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights
Continued site activation in registrational SAFEGUARD trial of SAB-142; enrollment ongoing and on track to be completed by end of 2026 with topline data expected in 2H 2027SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET
MIAMI, May 05, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that its first quarter 2026 financial results will be issued in the morning of Tuesday, May 12, 2026. Management will host a conference call and webcast at 8:30 AM ET to discuss the results and provide business updates.Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142
GAITHERSBURG, Md., April 29, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a multi-year agreement with SAB Biotherapeutics, Inc. (Nasdaq: SABS, SAB BIO) to support the process development and manufacturing of SAB-142, SAB BIO’s lead program in clinical development for autoimmune type 1 diabetes (T1D). The executed agreement is valued at approximately $50 million, of which $36 million is contingent on future regulatory approval and downstream milestones.SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026
All 4 T1D participants receiving SAB-142 showed C-peptide preservation with 3 of the 4 participants showing a super responder profile concomitant with T cell exhaustion
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding SAB Bio
Sign Up For FreeTo access detailed company insights
SAB Biotherapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing human polyclonal antibody therapeutics to treat and prevent infectious diseases and immune and autoimmune disorders. Headquartered in Sioux Falls, South Dakota, SAB Biotherapeutics has pioneered a proprietary platform technology called DiversitAb, which uti... Read More
